Adicet bio to present three scientific posters highlighting its allogeneic gamma delta t cell platform and programs at the society for immunotherapy of cancer (sitc) 38th annual meeting

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for cancer, today announced the acceptance of three abstracts for a poster presentation at the upcoming society for immunotherapy of cancer (sitc) 38th annual meeting to be held in san diego, ca from november 1-5, 2023. details of the poster presentation are as follows: abstract title: assay development and qua.
ACET Ratings Summary
ACET Quant Ranking